U.S. FDA Approves First PD-L1 Blocker for cSCC

December 16, 2024

Blue’s Clues: Research Explores How Blue Light Affects Skin

December 12, 2024

Meta-analysis: Castle Biosciences’ DecisionDx-Melanoma Test Accurately Stratifies Patients based on Risk of Recurrence and Metastasis

December 12, 2024

Elucidating Prostaglandin E2’s Role in Senescence and Neoplastic Escape in Human Keratinocytes

December 10, 2024

CeraVe, La Roche-Posay, Dermalogica, and Others Take Home 2024 CEW Beauty Awards

November 22, 2024

SpotCheck Teledermoscopy Tool Can Be Highly Accurate in Diagnosing Melanoma

November 16, 2024

ASDS 2024: Results From DecisionDx-Melanoma and DecisionDx-SCC Help Guide Skin Cancer Treatment Decisions

October 21, 2024

New AI Model Trumps 7PCL and Williams Score for Spotting Skin Cancers

October 17, 2024

Castle Biosciences, Inc.’s DecisionDx-SCC Better IDs High-risk Immune-suppressed SCC Patients Who Need ART

September 30, 2024

“Practice-changing” Results: Long-term Advanced Melanoma Survival Dramatically Improves on Immunotherapy

September 15, 2024

Study Examines Sex-specific Trends in Melanoma

September 15, 2024

Image-Guided SRT Boasts Consistent High Freedom From Recurrence of Nonmelanoma Skin Cancer Regardless of Age or Sex

September 13, 2024